192 related articles for article (PubMed ID: 10087958)
1. [Problems in oncologic pharmacology].
Filov VA; Gershanovich ML; Akimov MA; Akimov AA
Vopr Onkol; 1998; 44(6):651-61. PubMed ID: 10087958
[No Abstract] [Full Text] [Related]
2. New drugs target hypoxia response in tumors.
Garber K
J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066
[No Abstract] [Full Text] [Related]
3. [Update on antitumor pharmacology: reality and perspectives in 1998].
Lavelle F; Jehanno A
Bull Cancer; 1998 Jan; 85(1):83-8. PubMed ID: 9752357
[No Abstract] [Full Text] [Related]
4. BAY12-9566. BAY 12 9566, BAY12 9566.
Drugs R D; 1999 Feb; 1(2):142-3. PubMed ID: 10566009
[No Abstract] [Full Text] [Related]
5. Angiogenesis research enjoys growth spurt in the 1990s.
Ziegler J
J Natl Cancer Inst; 1996 Jun; 88(12):786-8. PubMed ID: 8637041
[No Abstract] [Full Text] [Related]
6. CGS 27023A. CDG 27023A.
Drugs R D; 1999 Feb; 1(2):144-5. PubMed ID: 10566010
[No Abstract] [Full Text] [Related]
7. Marimastat. BB 2516, TA 2516.
Drugs R D; 1999 Feb; 1(2):146-9. PubMed ID: 10566011
[No Abstract] [Full Text] [Related]
8. AE 941--Neovastat.
Drugs R D; 1999 Feb; 1(2):135-6. PubMed ID: 10566006
[No Abstract] [Full Text] [Related]
9. Lessons learned from marketed and investigational prodrugs.
Ettmayer P; Amidon GL; Clement B; Testa B
J Med Chem; 2004 May; 47(10):2393-404. PubMed ID: 15115379
[No Abstract] [Full Text] [Related]
10. The era of cancer discovery.
Cantley LC; Baselga J
Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
[No Abstract] [Full Text] [Related]
11. [Anti-angiogenesis: a new concept in therapy of solid malignancies?].
Schweigerer L
Med Klin (Munich); 1995 Dec; 90(12):709-12. PubMed ID: 8583988
[No Abstract] [Full Text] [Related]
12. AN-9 (Titan).
Hobdy E; Murren J
Curr Opin Investig Drugs; 2004 Jun; 5(6):628-34. PubMed ID: 15242252
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of angiogenesis in the treatment of tumors.
Ostrowski K; Kinsner A
Arch Immunol Ther Exp (Warsz); 2001; 49(1):27-31. PubMed ID: 11266087
[TBL] [Abstract][Full Text] [Related]
14. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
15. [Problems associated with molecular targeted drugs for cancer].
Kawaishi M; Koizum F; Nishio K
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1373-9. PubMed ID: 17033223
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
17. OSI-461 (OSI).
Galmarini CM
Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
[TBL] [Abstract][Full Text] [Related]
18. New checkpoint blockers begin human trials.
Garber K
J Natl Cancer Inst; 2005 Jul; 97(14):1026-8. PubMed ID: 16030295
[No Abstract] [Full Text] [Related]
19. Cancer stem cells: getting to the root of cancer.
Azvolinsky A
J Natl Cancer Inst; 2012 Jun; 104(12):893-5. PubMed ID: 22715190
[No Abstract] [Full Text] [Related]
20. New sources and new antitumor drugs in development.
Weiss RB
Semin Oncol; 1997 Apr; 24(2):153-5. PubMed ID: 9129685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
